| The Diabetes Care division posted yet another year of exemplary growth garnering 3.3% market share of the overall Indian diabetes market. In FY 2010, the Company's Diabetes business grew at 44% as against the Industry growth rate of around 24%. Lupin is ranked 8th overall in the (Oral+Insulin) diabetic market growing at twice the market rate. The division launched two new brands during FY 2010.
Key Products : Lupin Diabetes Care
|
Product |
Therapeutic Segment |
Product Rank in the relevant segment |
|
Misobit |
Miglitol |
1 |
|
Telista |
Telmisartan |
2 |
|
Gabastar |
Gabapentin |
2 |
|
Matilda |
Mecobalamin |
2 |
|
Lipril |
Lisinopril |
2 |
|
Gluconorm |
Diabetics orals |
3 |
| 
